Advisor Group’s Atossa Therapeutics ATOS Stock Holding History

Advisor Group’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28	Closed	-$1K	–	5092
2018 Q3	$1K	Hold	28	–	–	﹤0.01%	4933
2018 Q2	$1K	Hold	28	–	–	﹤0.01%	4770
2018 Q1	$2K	Buy	+28	New	+$2.61K	﹤0.01%	4665

Other funds holding ATOS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Advisor Group's ATOS Position: Q4 2018 in Review

Advisor Group sold out of Atossa Therapeutics (ATOS) in Q4 2018, closing a stake of 28 shares — an estimated $1K sold.

Advisor Group first reported a position in ATOS in Q1 2018 and held it in 3 quarters. The position peaked at $2K in Q1 2018. 18 funds tracked by Wall St. Rank hold ATOS as of Q4 2018.

Advisor Group reported no remaining Atossa Therapeutics position as of Q4 2018 after selling out during the quarter.
Advisor Group sold 28 Atossa Therapeutics shares in Q4 2018, an estimated $1K.
Advisor Group first reported a position in Atossa Therapeutics in Q1 2018 and held it in 3 quarters.
Advisor Group's Atossa Therapeutics position peaked at $2K in Q1 2018.
18 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2018.

Based on Advisor Group's 13F filing for Q4 2018, filed 11 Feb 2019.